Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another virus for the HP and AEMD: the Zika Virus:
http://www.rawstory.com/2016/01/the-zika-virus-could-be-heading-for-the-united-states-scientists-warn/
37,000 plus shares traded
$9.10 on yahoo
The hedge fund taking a position speaks volumes...
Interesting...europe....
TAUSOME submitted for TM by ESI in Jan 2015
comments from yahoo bd...
Is something happening with ESI? Is there a product going to be introduced since there is a trademark application made. Is this a catalyst reason for the RS and getting to NASDAQ? There are more studies released on tau other than ESI Boston studies that indicate tau is the issue - click2houstondotcom/news/doctors-closer-to-unlocking-mystery-surrounding-alzheimers-disease/32308624
Hmmmm
http://ind.ucsf.edu/research/true-stories/junior-seau
National Football League linebacker Junior Seau committed suicide in 2012, at the age of 43. A study by five independent brain experts reported that Seau's brain showed evidence of chronic traumatic encephalopathy (CTE). These signs included the presence of abnormal tau protein, which forms neurofibrillary tangles (NFTs). These protein deposits are also found in other brain diseases, including Alzheimer's disease and the frontotemporal dementias.
sounding like they have something related to their CTE study
Tauopathies
The tauopathies are a class of diseases caused by misfolding of the tau protein. Tau prions begin replicating spontaneously in the frontal lobes.
Tau prions are observed in frontotemporal dementia (FTD), posttraumatic stress disorders (PTSD), dementia pugilistica, and chronic traumatic encephalopathy (CTE), which has been seen in boxers, football and hockey players, and soldiers after episodes of traumatic brain injury (TBI).
Many symptoms of PTSD resemble those of the FTDs: changes in personality, behavior, sleep patterns and executive function dominate these illnesses. Behavioral alterations range from lethargy to disinhibition; apathetic patients may become socially withdrawn. Insomnia and nightmares are common, as are drug addiction and alcoholism. Violent mood swings from euphoria to depression can precede suicide.
TAUSOME
By: Exosome Sciences, Inc. tweet it Tweet Logo
Medical devices for extracorporeal therapeutics and diagnostics
Perfect for these industries
Words that describe this logo
Medical Instrument Products
medical devices extracorporeal therapeutics diagnostics
This is a brand page for the TAUSOME trademark by Exosome Sciences, Inc. in San Diego, CA, 92122. Write a review about a product or service associated with this TAUSOME trademark. Or, contact the owner Exosome Sciences, Inc. of the TAUSOME trademark by filing a request to communicate with the Legal Correspondent for licensing, use, and/or questions related to the TAUSOME trademark.
On Tuesday, January 27, 2015, a U.S. federal trademark registration was filed for TAUSOME by Exosome Sciences, Inc., San Diego, CA 92122. The USPTO has given the TAUSOME trademark serial number of 86516168. The current federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER. The correspondent listed for TAUSOME is ROBERT J. HILTON of KNOBBE, MARTENS, OLSON & BEAR, LLP, 2040 MAIN ST FL 14, IRVINE, CA 92614-8214 . The TAUSOME trademark is filed in the category of Medical Instrument Products . The description provided to the USPTO for TAUSOME is Medical devices for extracorporeal therapeutics and diagnostics.
Interesting older (2012) AEMD interview:
www.aethlonmedical.com/assets/001/5127.pdf
"...or as a standalone cancer or hepatitis C therapy...") !?.....hmmmm
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that Exosome Sciences, Inc. will not be able to commercialize its future products, including any that can be described as a liquid biopsy, that the FDA will not approve the initiation of the Company's future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
?, Sure is getting interesting though...
Monday or Tuesday would be good timing for the release os a major development or two...
New Article on AEMD:
https://www.accesswire.com/viewarticle.aspx?id=427260&utm_source=dlvr.it&utm_medium=twitter
Excerpt on AEMD:
Speaking of Hepatitis C and External Blood Filters, Meet the HemoPurifier
As original as using liver cancer cells to function as an external liver is, there's another company working on an external blood filter of perhaps equal originality: using insecticides to filter viruses directly out of blood.
The idea of filtering out viruses from the blood is actually not science fiction. It's not quite standard of care for viral infections yet either, but it is definitely no longer strictly relegated to the realm of childhood fantasies. Aethlon Medical's (AEMD) Hemopurifier is the device that may yet break the viral-filtration barrier. In fact, the first stage of a two-stage clinical trial process for FDA approval is well under way.
While the process of filtering a virus out of the blood may seem complicated to the point of being magical, the concept behind the Hemopurifier is actually quite simple. Filtering viruses out can't be done simply by passing blood through tiny holes, because viruses are so small that doing such would filter everything out of the blood and leave the patient with nothing but salt water. And if you try to put some of the filtered material back in, you'll just end up putting the viruses back in, too.
But say you wanted to filter tiny iron filings out of a pile of marbles. All you'd have to do is use a magnet and you're done. The Hemopurifier uses what can be called a virus magnet made out of a material called galanthusnivalis agglutinin, or GNA. GNA is a naturally occurring molecule that comes from a plant called snowdrop. GNA is in a class of molecules called lectins, which are proteins that stick to sugars. Lectins are most widely employed in the food industry because they are mild pest controlling insecticides mostly nontoxic to humans. Genes that encode lectins have been crossed into mass-produced grains in order to ward off insects, and GNA specifically has been tested with wheat as an insecticide as well.
The special quality of GNA, however, is not its insecticidal potential for the food industry, but that it specifically sticks to sugars that happen to be on the surfaces of most viruses that circulate in the blood stream. These virus sugars are called glycoproteins, which are proteins with carbohydrate (sugar) tentacles that viruses use to attach themselves to cells and inject their genetic code into them. Glycoproteins are the hooks, the grapplers of viruses that let them infect your cells, and GNA grabs on to them like glue, allowing the rest of the blood to pass through.
The Hemopurifier basically consists of a tight cylindrical packing of GNA with plasma filters. It is attached as an added filtration unit to an existing dialysis machine, so no additional hardware is required.
Does it work?
While a large scale clinical trial is yet to be done with the Hemopurifier (Aethlon is currently enrolling patients 2 and 3 of 10 in a feasibility study) there is hard evidence that the Hemopurifier pulls viruses out of the blood with little to no side effects. In a 12-patient study of HCV patients conducted in India, no adverse events were reported, and 10 patients achieved a sustained virologic response, the technical term for a cure with HCV. 7 of those 10 acheived a rapid virologic reponse, which means a cure within 30 days of treatment. But the concreteness of the results is what they found in the Hemopurifier after each treatment on average, which was 300 billion copies of HCV.
There is even evidence that the filter works for Ebola as well. In late October 2014 when the last Ebola epidemic was at its peak in West Africa, Time Magazine reported that one patient from Sierra Leone arrived in Germany and progressed to multiple organ failure. He was treated with several experimental therapies including the Hemopurifier and was eventually cured. Doctors cannot say conclusively that the Hemopurifier cured him, but they can say conclusively that immediately before the filtration, his viral load was 400,000 copies per mL, and after it was only 1,000. It was this episode that prompted Time to name the Hemopurifier one of the top 25 inventions of 2014.
Regulatory Pathway
To get to where Aethlon is now was not easy. Convincing the FDA to allow even a feasibility study took 5 years of negotiations. Aethlon is now working with DaVita (DVA) to treat 10 patients with end stage renal disease who also happen to have HCV. Since they are on dialysis anyway, it's only a matter of plugging in the Hemopurifier to the machine they are already on and monitoring the virus. 3 patients have been treated out of 10, with results scheduled around October.
After that, since the Hemopurifier is not a new biologic drug, the regulatory pathway it must traverse from there to approval only requires one more pivotal clinical trial after the completion of the feasability study. There is no phase 3 like there is for Vital's ELAD.
Applications
The potential for the Hemopurifier does not end at HCV or even Ebola. Since almost all viruses are glued to GNA naturally, the device could theoretically work on any virus as long as it circulates in the blood stream, including incurable ones like herpes, and even HIV for which it has already been tested with encouraging results including a 55% reduction in viral load. For patients that have developed a tolerance to whatever antiviral therapy they have been using, it could be the only alternative once resistance takes hold. Viruses can develop resistance to a drug, but they cannot resist being glued to GNA in a filter.
Despite being public for 16 years already, Aethlon has been very frugal, burning through only $80M since inception in 1999. Vital, on the other hand has an accumulated deficit of over $140M. Much of that has to do with with extremely expensive nature of a pivotal phase 3 trial that Vital is currently conducting. ELAD, even though an external filter, is still a biologic and requires a phase 3. The Hemopurifier does not, since it is not a biologic.
Deleted, see the new article above...
Hopefully with the same result...
Clear...
Aethlon Medical’s Hemopurifier works on bacteria also (TB, sepsis…., not just viruses…)
Drug-Resistant Tuberculosis Could Kill 75 Million Over The Next 35 Years
http://www.huffingtonpost.com/2015/03/24/drug-resistant-tuberculosis_n_6927820.html
From an old AEMD PR:
Disclosure of First Bacterial Infection Data
•An in-vitro bacteriological study, under the collaboration of Jeffrey Schorey, Ph.D., of the Eck Institute of Global Health at the University of Notre Dame, demonstrated that the Hemopurifier®, in a 4-hour period, captured 97% of exosomes secreted by mycobacterium tuberculosis, the pathogenic bacterial agent that causes Tuberculosis. Dr. Schorey is a 2009 recipient of a Bill and Melinda Gates Foundation grant to study exosomes as a potential Tuberculosis vaccine.
Always a voice of reason dj
(and good one on iv about the eeyores and rabbits whinging at each other ad infinitum)
Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform
27 APR 2015 presentation likely to report further developments in 8 SEP 2014 news: Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce the Advancement of a Broad-Spectrum Cancer Detection and Monitoring Platform.
In the validation studies, ESI researchers provided evidence that their diagnostic platform could identify the presence of cancer in analyzed blood samples from individuals suffering from glioblastoma, metastatic melanoma, breast cancer, ovarian cancer, colorectal cancer and pancreatic cancer. Beyond the potential implications in diagnosing cancer, ESI researchers believe the high-sensitivity of the platform will allow for effective monitoring of cancer progression and response to corresponding therapies. In oncology indications, the sensitivity of the ESI platform also represents an advancement over the ELLSA assay that was originally developed by Aethlon Medical to quantify changes in circulating exosome load resulting from the administration of Aethlon Hemopurifier® therapy. Based on previously reported discoveries related to progressive neurodegenerative disorders, Aethlon further disclosed that the ESI team has initiated follow-on studies to advance a candidate blood test to identify and monitor the progression of Chronic Traumatic Encephalopathy (CTE). At present, CTE is only diagnosed through postmortem autopsy. CTE has been most commonly found at autopsy in former National Football League (NFL) players and has also been demonstrated to be prevalent in soldiers exposed to blast injury. In previous disclosures, ESI researchers reported that they had successfully isolated brain-specific biomarkers that could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), CTE and Glioblastoma Multiforme (GBM). The studies provided evidence that the ESI platform could also detect exosomes as a basis for a "liquid biopsy" to diagnose neurologic conditions.
kslate yhoo
After looking at it...Looks totally meaningless....
After looking at it...Looks totally meaningless....
I got the same reply...at least they know they can use the HP now...which they may or may not have known before.
AEMD Legitimacy Proven Again and Again
Pasted from Zacks 10/2/13 Research Report Update.
AEMD has consistently and timely hit milestones under the DARPA contracts and has been rewarded with the follow-on contracts, which we think provides insight into the R&D capabilities of the company as well as lending a vote of confidence in the technology from DARPA, which has been instrumental in the development of a number of high profile products and services (including the internet, the Stealth Fighter and M16 assault rifle, among others). Many technologies initially funded by DARPA are not only in widespread use by the military but are also being used in commercial products.
We're getting closer and closer to the time we can smell the shorts not just frying but charred.
Great post DJ...
Don't let the door hit you twice on the way out-get lost (skydog)
If you don't like the company, be somewhere else...
http://www.cnn.com/2015/02/13/health/are-we-ready-for-global-outbreak/
AEMD seems like a no-brainer for the treatment of a lot of upcoming (and existing) medical nightmares...instead of the phrase: Give Peace A Chance, make it: Give Healing A Chance....(Free the HP instead of Free the N---le)
11:00 am Detecting Tau: State of the Art Potential Biomarkers for Chronic Traumatic Encephalopathy
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with a history of repetitive brain trauma. At this time, the diagnosis of CTE can only be made through neuropathological examination. However, in order to investigate critical issues pertaining to CTE, such as its incidence and prevalence and specific risk factors, as well as to conduct clinical trials for the prevention and treatment of the disease, it is necessary to develop accurate methods of in vivo diagnosis. A hallmark feature of the neuropathology of CTE is the deposition of hyperphosphorylated tau (p-tau) as neurofibrillary tangles (NFT) beginning perivascularly and at the depths of the cortical sulci. This talk will present data from the DETECT study of former professional American football players, focusing on preliminary findings of two potential biomarkers for p-tau in CTE: (1) a blood-based measure of brain-derived exosomal tau (Exosome Sciences) and the T807 (AV1451) PET tau radiotracer (Avid Radiopharmaceutical).
Robert A. Stern, Ph.D., Professor of Neurology, Neurosurgery, and Anatomy and Neurobiology, Director of Clinical Research, CTE Center, Clinical Core Director, BU Alzheimer’s Disease Center, Boston University School of Medicine
(Avid Radiopharmaceuticals, Inc.
a wholly owned subsidiary of Eli Lilly and Company)
Gotta love all the armchair CEO's on the AEMD mb's....some decisions are not up to AEMD.
Thanks for the clarification...
Response from JJ on my question regarding CTE results
Thank you for your inquiry regarding our CTE research program. As previously referenced in “The Chairman’s Blog”, I have an inspired interest to establish a blood-based test that could unlock the ability to diagnose and monitor the progression of this neurological disorder.
Specific to your question, our Exosome Sciences subsidiary remains actively involved in the NFL DETECT study through a collaboration with the Boston University CTE Center. Jointly, we are now working to determine the appropriate venue to present and/or publish our data.
From Yahoo Bd nimbg4
January's top stories: Siemens smart hearing aids, Aethlon's Hemopurifier
3 February 2015 Nancy Victor
FDA approves Aethlon's Ebola treatment protocol
hemopurifier
The US Food and Drug Administration (FDA) granted approval for Aethlon Medical's clinical protocol to treat Ebola-infected individuals with its Hemopurifier in the US.
The Aethlon Hemopurifier is a bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals.
Hemopurifier targets antiviral drug resistance and is a first-line countermeasure against Ebola and other viruses, which are not tackled with proven drug therapies.
http://www.medicaldevice-network.com/features/featurejanuary-top-stories-2015-4502428/
Patents
from the S-1 As filed with the Securities and Exchange Commission on December 31, 2014
We have been exclusively assigned all rights and title to and interest in an invention and related worldwide patent rights for a method to treat cancer under an assignment agreement with the London Health Science Center Research, Inc. The invention provides for the "Depression of anticancer immunity through extracorporeal removal of microvesicular particles" (including exosomes) for which the U.S. Patent and Trademark Office allowed a patent in 2012 (patent #8,288,172) and for which we have filed additional patent applications domestically and abroad (patent applications #13/623662, #14/180093, #14/185033, #7,752,778.6, #9,104,740.6, #8139/DELNP/2008 and #2644855). Please see the tables below for more information regarding these patents and patent applications.
The agreement provides that we are responsible for paying certain patent application and filing costs as well as a 2% royalty on any future net sales. Under the license agreement, the London Health Science Center Research, Inc. sold and assigned all of its rights, title and interest in the worldwide patents to us.
from fearingsf ivb
They have a lot of irons in the fire, and any one of them could get things moving...
Telephone conversation W/JJ
I sent this to a friend and was not going to post it as I felt it was somewhat private communication; but I got so weary of all the management, (especially JJ), bashing I felt I had to,
I had a long conversation with him and here is a summary of what he said:
(When he said we you can assume he meant Aethlon)
While we were in the process of filing the Registration statement we faced very strict restrictions on public statements. We self imposed even stricter restrictions on ourselves to ensure we would face no problems with it being approved.
He also said that stockholders should be aware that Aethlon was still required to file any negative events during this period and --- There were none! (His emphasis.)
Now that the registration statement has been accepted we will be resuming regular public communications and any conferences would be open to all interested parties.
We talked about how most investors connect share price to the health and status of a company; but with smaller companies that does not always follow. There are many things that can influence the share price of a smaller company. (He discussed many of them; but I am sure we know what they are,)
Jim said 2015 is going to be a great year and He could not say any more at this time.
If you have any specific questions please email or call him. (THIS ALSO APPLY'S TO ANONE READING THIS POST.)
If my health holds up, we are going to meet for lunch in a few weeks. I will report back on anything of interest we discuss then.
Hope this helps shore up your confidence. I can tell you there were many things said by what he did not say in answer to several of my questions. I am charged after this talk. I wish we were on phone so I could be more open; but written words can come back to bite.
PhilB
From IVBd
Sounds like we will be getting some communication from Aemd soon according to the IV board, as it sounds like Aemd was in a quiet period.
Another virus that the HP might be able to help: If only someone had the guts to try it like they did in Frankfurt....
http://www.dailymail.co.uk/sciencetech/article-2936769/Mystery-virus-paralysing-children-Rare-bug-related-polio-caused-100-unexplained-cases.html
Typical (even for posters I have on ignore)
Typical slow downward drift in price for a penny stock which has experienced recent dramatic price appreciation followed by a quiet period.......looking forward to and hopeful for substantial developments in the near future...glta
AEMD Research Report By Redchip.com on InvestorIdeas.com
http://www.investorideas.com/CO/AEMD